MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.54
-0.40
-6.73%
After Hours: 5.54 0 0.00% 17:15 02/26 EST
OPEN
5.90
PREV CLOSE
5.94
HIGH
6.12
LOW
5.50
VOLUME
914.13K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
2.000
MARKET CAP
857.47M
P/E (TTM)
-5.8035
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: ADAPTIMMUNE THERAPEUTICS PLC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
Adaptimmune Therapeutics (ADAP) Receives a Hold from Mizuho Securities
Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $9.00. The company's
SmarterAnalyst · 1d ago
8-K: Adaptimmune Therapeutics PLC
(EDGAR Online via COMTEX) -- 0001621227false00-000000000016212272021-02-252021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.23) Estimate, Sales $1.50M Miss $1.98M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.23) by 82.61 percent. This is a 20 percent increase over losses of $(0.05) per share
Benzinga · 1d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 1d ago
BRIEF-Adaptimmune Reports Fourth Quarter Full Year 2020 Results, Business Update
reuters.com · 1d ago
Adaptimmune EPS beats by $0.19, beats on revenue
Adaptimmune (ADAP): Q4 GAAP EPS of -$0.04 beats by $0.19.Revenue of $1.5M (+105.5% Y/Y) beats by $0.65M.Press Release
Seekingalpha · 1d ago
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophago...
GlobeNewswire · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADAP. Analyze the recent business situations of Adaptimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADAP stock price target is 11.33 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 118.25M
% Owned: 76.40%
Shares Outstanding: 154.78M
TypeInstitutionsShares
Increased
26
17.05M
New
42
-6.90M
Decreased
19
21.84M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
Chief Executive Officer/Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Vice President/Director of Investor Relations
Sebastien Desprez
Vice President
Paul Stead
Senior Vice President
Elliot Norry
Other
John Lunger
Other
Helen Tayton-Martin
Non-Executive Director
James Noble
Non-Executive Independent Director
Lawrence Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
Barbara Duncan
Non-Executive Independent Director
John Furey
Non-Executive Independent Director
Elliott Sigal
Non-Executive Independent Director
Elliot Sigal
Non-Executive Independent Director
Charles Sigal
Non-Executive Independent Director
Tal Zvi Zaks
Non-Executive Independent Director
Tal Zaks
  • Dividends
  • Splits
  • Insider Activity
No Data
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.